Founded in 2018, Enteral Access Technologies (EAT) designs patient-safety devices that simplify and safeguard nasogastric and orogastric tube placement. Its flagship product, DoubleCHEK, integrates CO₂ and pH detection into a single disposable device, reducing misplacement risk and eliminating the need for special tubes or extra equipment. The product is gaining traction in the UK as hospitals align with updated guidance supporting combined CO₂ + pH confirmation, and it is seeing repeat orders across early European adopters such as Italy. In the U.S., uptake accelerated after a leading children’s hospital adopted DoubleCHEK and a competing product was withdrawn. EAT positions DoubleCHEK as a workflow-streamlining alternative that also reduces radiation exposure from X-ray confirmation. The company plans to use new capital to scale international rollout and continue product development. Although no revenue figures were disclosed, management points to strong initial uptake and repeat orders as evidence of commercial momentum.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025